

Understanding Individualized Risk of Respiratory Morbidity to Guide Shared Decision-Making Around Late Preterm Steroids

Mark A. CLAPP, MD MPH¹, Siguo LI, MS¹, Jessica L. COHEN, PhD², Cynthia GYAMFI-BANNERMAN, MD, MS³, Anjali J. KAIMAL, MD MAS⁴, Amy B. KNUDSEN, PhD⁵, Scott A LORCH, MD, MSCE⁶, Tanayott THAWEETHAI, PhD⁷, Jason D. WRIGHT, MD⁸, Alexander MELAMED, MD MPH¹

¹ Department of Obstetrics, Gynecology, and Reproductive Biology, Massachusetts General Hospital

² Department of Global Health and Population, Harvard T.H. Chan School of Public Health

³ Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Diego

⁴ Department of Obstetrics and Gynecology, University of South Florida

⁵ Institute of Technology Assessment, Department of Radiology, Massachusetts General Hospital

⁶ Division of Neonatology, Children's Hospital of Philadelphia

⁷ Division of Biostatistics, Massachusetts General Hospital

⁸ Department of Obstetrics and Gynecology, Columbia University

Disclosures: Dr. Clapp reports grants from the Society for Maternal-Fetal Medicine and the Risk Management Foundation of the Harvard Medical Institutions, Inc., and serves as a medical advisory board member with private equity in Delfina Health, outside the submitted work. Dr. Melamed reports grants from the National Center for Advancing Translational Sciences, the National Cancer Institute, and the Conquer Cancer-The ASCO Foundation, and the Department of Defense outside the submitted work. Dr. Melamed has also served as an advisor for AstraZeneca. Dr. Wright has received research funding from Merck and honoraria from UpToDate. Dr. Gyamfi-Bannerman reports grants from NHLBI, NICHD and NIHMD and has received research funding from HealthCore Inc/SERA Prognostics, Inc and MIRVIE, Inc.

Conflicts of interest: The authors declare no conflicts of interest or financial support for this project.

Acknowledgments: The authors have no acknowledgments.

Word Count:

Main – 2,457

Abstract - 347

Abstract

Objective: To estimate the effect of antenatal steroids on the absolute risk of respiratory morbidity among subgroups of patients based on two clinical factors with known varying baseline risks of morbidity: planned mode of delivery and gestational age at presentation.

Methods: This is a secondary analysis of the Antenatal Late Preterm Steroid (ALPS) Trial, a study that randomized individuals at high risk for late preterm delivery (34-36 weeks of gestation) to antenatal steroids or placebo. We fit logistic regression models to estimate the absolute risk of respiratory morbidity, with and without steroid administration, by gestational age and planned mode of delivery at the time of presentation. We assumed a homogenous effect of steroids on the log-odds scale, as was reported in the ALPS trial. To aid in shared decision-making, we report absolute risks of neonatal respiratory complications with and without steroid administration graphically, in tabular form, and via an online tool available at XXX.

Results: The analysis included 2,825 patients at risk for late preterm birth. The risk of respiratory morbidity varied significantly by planned mode of delivery (adjusted odds ratio (aOR) 2.19 (95% confidence interval (CI) 1.68, 2.85) for cesarean compared to vaginal delivery) and day of gestation at presentation (aOR 0.91 (95% CI 0.89, 0.93)). For those planning a cesarean delivery and presenting in the 34th week of gestation, the risk of neonatal respiratory morbidity was 36.7% (95% CI 29.8, 43.7%) without steroids and 31.4% (95% CI 24.5, 37.9%) with steroids. In contrast, for patients presenting in the 36th week and planning a vaginal delivery, the risk of neonatal respiratory morbidity was 6.8% (95% CI 5.1, 8.5%) without steroids and 5.4% (95% CI 4.0, 6.9%) with steroids.

Conclusion: The absolute risk of neonatal respiratory morbidity among patients at risk for late preterm delivery varies considerably by gestational age at presentation and planned mode of

delivery. As communicating only the relative risk reduction of antenatal steroids for respiratory morbidity may exaggerate the perception of benefit, especially for those with a small absolute risk, individualized estimates of absolute risk expected with and without treatment may inform shared decision-making.

Introduction

Neonatal respiratory morbidity, including respiratory distress syndrome and transient tachypnea of the newborn, is a common complication of prematurity.¹⁻³ Multiple patient factors, including gestational, mode of delivery, and fetal sex, influence the risk of respiratory morbidity.²⁻⁷ There is a broad and longstanding consensus that antenatal steroids decrease the risk of neonatal respiratory morbidity for neonates born before 34 weeks of gestation.^{8,9} More recently, the Antenatal Late Preterm Steroid (ALPS) Trial demonstrated that this benefit extends to fetuses at risk of delivery in the late preterm period (34-36 weeks of gestation): neonates exposed antenatally to betamethasone in the late preterm period had a 20% risk reduction of the composite respiratory outcome, without statistically conclusive evidence of treatment heterogeneity among pre-specified subgroups.¹⁰

The Society for Maternal-Fetal Medicine recommends that clinicians and patients engage in shared decision-making around steroid administration in the late preterm period.¹¹ However, the baseline risk of respiratory morbidity differs substantially across the late preterm period, making summary measures of absolute risk, as reported in the original trial, less informative for individualized counseling.² Furthermore, communicating only the relative risk may exaggerate the perception of the benefit of antenatal steroids, especially for those with a small absolute risk.¹² Thus, our objective in this secondary analysis of data from the ALPS Trial was to estimate the absolute risk of respiratory morbidity with and without steroid administration, based on patients' planned mode of delivery and gestational age at presentation.¹⁰

Methods

This is a secondary analysis of the Antenatal Late Preterm Steroid (ALPS) Trial conducted within 17 university-based hospitals within the Maternal-Fetal Medicine Units (MFMU).¹⁰ In the trial, patients with a singleton pregnancy between 34 weeks 0 days and 36 weeks 5 days of gestation and with a high chance of delivery in the late preterm period were enrolled and randomized to receive an antenatal course of betamethasone or placebo. The primary outcome was a composite of respiratory morbidity within 72 hours after delivery and included the following: high-flow nasal cannula or continuous positive airway pressure (CPAP) for at least 2 hours; supplemental oxygen use for at least 4 hours; extracorporeal membrane oxygenation (ECMO); and/or mechanical ventilation. We also examined the secondary outcome of severe respiratory complications, as defined in the ALPS Trial as “a composite outcome of CPAP or high-flow nasal cannula for at least 12 continuous hours, supplemental oxygen with a fraction of inspired oxygen of at least 0.30 for at least at least 24 continuous hours, ECMO or mechanical ventilation, stillbirth, or neonatal death within 72 hours after delivery.”¹⁰ The ALPS trial randomized 2,831 patients to betamethasone (n=1,429) or placebo (n=1,402).¹⁰ This analysis included patients randomized at or after 34 weeks of gestation who were not lost to follow-up.

We examined the risk of neonatal respiratory morbidity among two patient factors strongly associated with the risk of respiratory morbidity: mode of delivery and gestational age.^{2,3,5} To generate results that could guide clinical decision-making and inform counseling, we considered *planned* mode of delivery (not actual mode) and gestational age *at presentation* (not delivery), information available to clinicians and patients when deciding about antenatal steroid administration. We defined the planned mode of delivery as “cesarean” if 1) a cesarean delivery was scheduled in the late preterm period at the time of presentation or 2) if no delivery was

scheduled at the time of presentation but a cesarean section was performed at any gestational age for the following indications: placenta accreta, placenta previa, fetal anomaly, prior uterine surgery, or prior cesarean delivery. This definition was chosen to capture patients who were unlikely to attempt a trial of labor. The prevalence of these factors was compared between the two groups to examine for potential group imbalances in the original trial.

We constructed a logistic regression model that included the treatment assignment (placebo or betamethasone), planned mode of delivery, and gestational age in days. Because the prespecified subgroup analysis in the original trial did not detect signs of treatment effect heterogeneity, the model assumed a constant effect size (on the log-odds scale) of the intervention across all groups. We used this regression model to estimate the absolute risks of respiratory morbidity in both the treated and untreated groups. The predicted (or estimated) absolute risks of this model were presented graphically by planned mode of delivery and across days of gestation; for comparison, we also plotted the observed absolute risks of the outcome with a corresponding 95% confidence interval by planned mode of delivery and weeks of gestation. To examine the model's discrimination and calibration, we used k-fold cross-validation (k=10) to calculate the area under the receiver operating characteristic (ROC) curves (AUC) and generate a calibration plot for both outcomes. Hosmer-Lemeshow tests were also used to assess calibration for the cross-validated model.

Additional steps were performed to further facilitate counseling around the absolute risk of respiratory morbidity and expected outcome by mode of delivery and gestational age. First, the risks of the primary and secondary outcomes were estimated using the same logistic regression model, though gestational age in weeks was used instead of gestational age in days; this allowed for the output to be summarized in a compact, interpretable table. Second, we built

an online reference tool to display the estimated risk of the primary and secondary outcome using a patient's precise gestational age in days at presentation and their planned mode of delivery, which is available at XXX.

Data was obtained with permission from the NICHD Data and Specimen Hub (DASH).¹³ The Mass General Brigham Institution Review Board exempted this study. All analyses used Stata (Stata Corp, College Station, TX). P-values <0.05 were considered statistically significant.

Results

Of the original 2,831 participants, we excluded 2 patients randomized before 34 weeks of gestation and 4 patients lost to follow-up (2.1%). Supplemental Table 1 shows the sample sizes of the various strata used in the analysis. As expected, there were no differences in distributions of the planned mode of delivery or gestational age at randomization between the two groups (Supplemental Table 2).

Figure 1 shows the predicted absolute risks of respiratory morbidity among patients treated with steroids and those who did not by the day of gestation and the planned mode of delivery at the time of presentation. The observed rates (not predicted by the model) by week of gestation are shown on the same graph for comparison and included in Supplemental Table 3. The risk of respiratory morbidity varied significantly across planned modes of delivery (adjusted odds ratio (aOR) 2.19 (95% confidence interval (CI) 1.68, 2.85) for cesarean compared to vaginal delivery) and day of gestation at presentation (aOR 0.91 (95% CI 0.89, 0.93)). The unadjusted and adjusted model outputs are shown in Supplemental Table 4. The 10-fold cross-validated AUC was 0.669 (95% CI 0.639, 0.698) (ROC curve shown in Supplemental Figure 1).

The calibration plot (Supplemental Figure 1) and the Hosmer-Lemeshow test (p-value=0.32) indicated that the model was well-calibrated.

The predicted absolute risks with and without treatment are summarized by week of gestation in Table 1. At baseline (i.e., among those treated with the placebo), neonates born to individuals planning a cesarean delivery have a 36.7% (95% CI 29.8, 43.7%) risk of respiratory morbidity when presenting in the 34th week of gestation; this risk decreases to 31.4% (95% CI 24.5, 37.9%) with antenatal steroids. By contrast, neonates who are born via a planned vaginal delivery after presenting in the 36th week of gestation have a 6.8% (95% CI 5.1, 8.5%) risk of respiratory morbidity without steroids and a 5.4% (95% CI 4.0, 6.9%) risk with steroid treatment.

Figure 2 shows the predicted absolute risks of severe respiratory complications among those who received and did not receive antenatal steroids by day of gestational age and planned mode of delivery. The observed risks are shown on the same graphs by week of gestation and are included in Supplemental Table 5. Planned mode of delivery (aOR 2.46 (95% CI 1.85, 3.29) for cesarean vs. vaginal delivery) and gestational age (aOR 0.91 (95% CI 0.88, 0.93)) were significantly associated with the risk of severe respiratory complications. The unadjusted and adjusted model outputs are shown in Supplemental Table 6. The 10-fold cross-validated AUC was 0.679 (95% CI 0.651, 0.717) (ROC curve shown in Supplemental Figure 1). The calibration plot (Supplemental Figure 1) and the Hosmer-Lemeshow test (p-value=0.58) indicated that the model was well-calibrated. These findings are summarized by week of gestation in Table 2 which tabulates the absolute risk of severe respiratory complication, with and without treatment, by planned mode of delivery and week of gestational age at presentation.

The results of these two models are available as an interactive calculator available at XXX. This tool displays the estimated absolute risk of respiratory morbidity (and associated 95% CIs) with and without treatment as a function of day of gestation at presentation and planned mode of delivery (example shown in Figure 3).

Discussion

In this secondary analysis of the ALPS Trial, we demonstrated how the absolute risks of neonatal respiratory morbidity vary significantly by gestational age and planned mode of delivery. Notably, infants born via a planned cesarean delivery are at a much higher risk of respiratory morbidity than those having a vaginal delivery, especially at earlier gestational ages (approximately 37% for planned cesarean delivery at 34 weeks vs. 7% for planned vaginal delivery at 36 weeks). While these relationships were previously known, we quantified this risk in the late preterm period using prospectively collected data as part of the ALPS Trial. This information (available online at XXX) can inform shared decision-making about late preterm steroids and allow clinicians to estimate the baseline risk of neonatal respiratory morbidity more accurately. This absolute baseline risk of respiratory in the unexposed group can then be used to interpret the expected relative risk reduction that was demonstrated uniformly across all enrollees in the trial.

These findings must be interpreted in the context of the original ALPS Trial protocol and the trial enrollees. The ALPS Trial only enrolled patients who were at high risk of a late preterm delivery as determined by predefined clinical factors (rupture of membranes, preterm labor at ≥ 3 cm dilation or $\geq 75\%$ effacement, or expected preterm delivery via induction or cesarean within 24 hours and 7 days) or provider judgment who had not previously received antenatal

corticosteroids or had pregestational diabetes.¹⁰ As a result, nearly 40% of enrollees delivered before receiving the second dose, and the median time from presentation to delivery was approximately 30 hours.¹⁰ The absolute risks reported from this trial are most relevant to patients presenting with a similar risk of preterm delivery. For example, the benefit of antenatal steroids may be higher than reported in the trial for patients who are more likely to deliver after receiving a full course; in contrast, the benefit may be less if more patients received antenatal steroids but went on to delivery at later gestations or full term (i.e., a lower risk of preterm delivery than the trial). Studies of late preterm antenatal steroids outside of the context of a clinical trial are needed to better estimate the absolute risks of respiratory morbidity and the benefit of the intervention.

The original trial did include subgroup comparisons for several factors, including planned cesarean delivery and gestational age, though gestational age was analyzed as 34-35 vs. 36 weeks of gestation. The study reported no significant effects for the interaction terms for the primary outcome when each factor was analyzed individually; however, the trial was not powered to detect differences in the primary outcome within subgroups. The possibility of a differential impact of betamethasone in actual practice (i.e., treatment effect heterogeneity) remains plausible, especially considering the differences in the number of days between first dose and delivery and the number of patients who received a full course of betamethasone before delivery by planned mode of delivery and gestational age at presentation. Investigations of treatment effect heterogeneity should be a focus of future research to further individualize counseling on risks and benefits.

This study focused on counseling regarding the individualized benefits of antenatal steroids among two common and known clinical factors across which the baseline risk of

respiratory morbidity varies widely. However, other factors may inform clinical decision-making, especially the known and theoretical intervention risks. Hypoglycemia, which was more likely in the treatment group in the ALPS Trial (RR 1.60 (95% CI 1.37-1.87)), also likely varies among population subgroups (e.g., gestational age).^{10,14,15} We could not investigate absolute risks of hypoglycemia across gestational age and mode of delivery because these data are not publicly available due to ongoing data collection at the time of this analysis.¹³ Furthermore, there is no data available to inform individualized counseling on the associations between long-term neurocognitive or developmental risks and antenatal steroids in the late preterm period. Available evidence in other populations is mixed, though a single dose of antenatal steroids in the early preterm period has not been shown to increase long-term neurodevelopment risks.¹⁶⁻²¹

The study is strengthened by its use of rigorously collected data as part of a large randomized controlled trial, allowing us to estimate the rates of respiratory morbidity among those exposed and unexposed to antenatal steroids in the late preterm period. However, it is limited in that the trial enrollees may not reflect the general population at risk for late preterm birth or considering antenatal steroids. As mentioned, the baseline risks of respiratory morbidity are presented for individuals with a high likelihood of delivery in the late preterm period.¹⁰ The baseline risks may vary in a population without the same likelihood of preterm delivery. Similarly, the original trial was not powered to detect differences within population subgroups. As such, the number of patients within our strata varies, some of which are small, leading to considerable uncertainty. To help quantify this uncertainty, 95% confidence intervals are provided in Tables 1 and 2 and in the online calculator.

In conclusion, the absolute risk of neonatal respiratory morbidity among patients at high risk for late preterm delivery varies considerably by gestational age at presentation and planned


mode of delivery. Assuming no treatment effect heterogeneity (i.e., a constant relative risk reduction among all subgroups), patients with a low baseline risk (e.g., those presenting in the 36th week and planning a vaginal delivery) can expect to obtain a considerably smaller absolute benefit from steroid administration compared to patients at the highest risk of neonatal respiratory morbidity (e.g., those presenting in the 34th week and planning a cesarean delivery). These findings may influence patient counseling on the expected benefit of antenatal steroids. Studies adequately powered to compare the risks and benefits of antenatal late preterm steroids among population subgroups, and their effectiveness outside the context of a clinical trial, are needed to increase the precision of shared decision-making and public policy surrounding late preterm steroids.

References

1. Mahoney AD, Jain L. Respiratory disorders in moderately preterm, late preterm, and early term infants. *Clin Perinatol*. 2013;40(4):665-678. doi:10.1016/j.clp.2013.07.004
2. Consortium on Safe Labor, Hibbard JU, Wilkins I, et al. Respiratory morbidity in late preterm births. *JAMA*. 2010;304(4):419-425. doi:10.1001/jama.2010.1015
3. De Luca R, Boulvain M, Irion O, Berner M, Pfister RE. Incidence of early neonatal mortality and morbidity after late-preterm and term cesarean delivery. *Pediatrics*. 2009;123(6):e1064-1071. doi:10.1542/peds.2008-2407
4. Mekic N, Selimovic A, Cosickic A, et al. Predictors of adverse short-term outcomes in late preterm infants. *BMC Pediatr*. 2023;23(1):298. doi:10.1186/s12887-023-04112-z
5. Berthelot-Ricou A, Lacroze V, Courbiere B, Guidicelli B, Gamorre M, Simeoni U. Respiratory distress syndrome after elective caesarean section in near term infants: a 5-year cohort study. *J Matern Fetal Neonatal Med*. 2013;26(2):176-182. doi:10.3109/14767058.2012.733743
6. Altman M, Vanpée M, Cnattingius S, Norman M. Risk factors for acute respiratory morbidity in moderately preterm infants. *Paediatr Perinat Epidemiol*. 2013;27(2):172-181. doi:10.1111/ppe.12035
7. Condò V, Cipriani S, Colnaghi M, et al. Neonatal respiratory distress syndrome: are risk factors the same in preterm and term infants? *J Matern Fetal Neonatal Med*. 2017;30(11):1267-1272. doi:10.1080/14767058.2016.1210597
8. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*. 2006;(3):CD004454. doi:10.1002/14651858.CD004454.pub2
9. Gilstrap LC, Christensen R, Clewell WH, et al. Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes: NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. *JAMA*. 1995;273(5):413-418. doi:10.1001/jama.1995.03520290065031
10. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. *New England Journal of Medicine*. 2016;374(14):1311-1320. doi:10.1056/NEJMoa1516783
11. Reddy UM, Deshmukh U, Dude A, Harper L, Osmundson SS. Society for Maternal-Fetal Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late preterm delivery: Replaces SMFM Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016. *American Journal of Obstetrics & Gynecology*. 2021;225(5):B36-B42. doi:10.1016/j.ajog.2021.07.023


12. Freeman ALJ. How to communicate evidence to patients. *Drug Ther Bull.* 2019;57(8):119-124. doi:10.1136/dtb.2019.000008
13. NICHD DASH - Eunice Kennedy Shriver National Institute of Child Health and Human Development Data and Specimen Hub. Accessed November 11, 2023. <https://dash.nichd.nih.gov/>
14. Bromiker R, Perry A, Kasirer Y, Einav S, Klinger G, Levy-Khademi F. Early neonatal hypoglycemia: incidence of and risk factors. A cohort study using universal point of care screening. *The Journal of Maternal-Fetal & Neonatal Medicine.* 2019;32(5):786-792. doi:10.1080/14767058.2017.1391781
15. Lubchenco LO, Bard H. INCIDENCE OF HYPOGLYCEMIA IN NEWBORN INFANTS CLASSIFIED BY BIRTH WEIGHT AND GESTATIONAL AGE. *Pediatrics.* 1971;47(5):831-838. doi:10.1542/peds.47.5.831
16. Räikkönen K, Gissler M, Tapiainen T, Kajantie E. Associations Between Maternal Antenatal Corticosteroid Treatment and Psychological Developmental and Neurosensory Disorders in Children. *JAMA Network Open.* 2022;5(8):e2228518. doi:10.1001/jamanetworkopen.2022.28518
17. Ninan K, Liyanage SK, Murphy KE, Asztalos EV, McDonald SD. Evaluation of Long-term Outcomes Associated With Preterm Exposure to Antenatal Corticosteroids: A Systematic Review and Meta-analysis. *JAMA Pediatrics.* 2022;176(6):e220483. doi:10.1001/jamapediatrics.2022.0483
18. van der Merwe JL, Sacco A, Toelen J, Deprest J. Long-term neuropathological and/or neurobehavioral effects of antenatal corticosteroid therapy in animal models: a systematic review. *Pediatr Res.* 2020;87(7):1157-1170. doi:10.1038/s41390-019-0712-1
19. Thevathasan I, Said JM. Controversies in antenatal corticosteroid treatment. *Prenatal Diagnosis.* 2020;40(9):1138-1149. doi:10.1002/pd.5664
20. Dalziel SR, Lim VK, Lambert A, et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. *BMJ.* 2005;331(7518):665. doi:10.1136/bmj.38576.494363.E0
21. Sotiriadis A, Tsiami A, Papatheodorou S, Baschat AA, Sarafidis K, Makrydimas G. Neurodevelopmental Outcome After a Single Course of Antenatal Steroids in Children Born Preterm: A Systematic Review and Meta-analysis. *Obstet Gynecol.* 2015;125(6):1385-1396. doi:10.1097/AOG.0000000000000748

Figure 1: Risk of respiratory morbidity among individuals exposed and not exposed to antenatal steroids by gestational age and planned mode of delivery



The lines represent the estimated rates of respiratory morbidity among those exposed (+ ALPS) and not exposed (- ALPS) that were derived from a logistic regression model that included gestation age at presentation (in days), planned mode of delivery (vaginal vs. cesarean), and treatment group. For comparison, the observed rates (i.e., “actual risk”) with their corresponding 95% confidence interval (CI) by week (not day) of gestation are also plotted; of note, their position on the x-axis does not correspond to a specific day within the week of gestation.

Figure 2: Risk of severe respiratory complications among individuals exposed and not exposed to antenatal steroids by gestational age and planned mode of delivery



The lines represent the estimated rates of severe respiratory complications among those exposed (+ ALPS) and not exposed (- ALPS) that were derived from a logistic regression model that included gestation age at presentation (in days), planned mode of delivery (vaginal vs. cesarean), and treatment group. For comparison, the observed rates (i.e., “actual risk”) with their corresponding 95% confidence interval (CI) by week (not day) of gestation are also plotted; of note, their position on the x-axis does not correspond to a specific day within the week of gestation.

Figure 3: Image of online calculator to estimate the absolute risks of respiratory morbidity by planned mode of delivery and gestational age with and without antenatal steroids

Absolute Risk of Respiratory Morbidity for Neonates at High Risk for Late Preterm Birth



*Notes: Estimated risks were calculated from the ALPS Trial data and using a logistic regression model with the treatment group as the independent variable and gestational age at presentation (in days) and planned mode of delivery as covariates. Absolute risks are presented with a corresponding 95% confidence interval.

Outcome Definitions

Respiratory Morbidity

Respiratory support <72 hours after birth is defined as any of the following: the use of CPAP or high-flow nasal cannula for ≥ 2 consecutive hours, supplemental oxygen with a $\text{FiO}_2 \geq 0.30$ for ≥ 4 continuous hours, ECMO, or mechanical ventilation.

Severe Respiratory Complication

Defined as any of the following: CPAP or high-flow nasal cannula for ≥ 2 continuous hours, supplemental oxygen with $\text{FiO}_2 \geq 0.30$ for ≥ 24 continuous hours, ECMO or mechanical ventilation, stillbirth, or neonatal death within 72 hours after delivery.

References:

1. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. *New England Journal of Medicine*. 2016;374(14):1311-1320. doi:10.1056/NEJMoa1516783
2. NICHD DASH - Eunice Kennedy Shriver National Institute of Child Health and Human Development Data and Specimen Hub. Accessed November 11, 2023. <https://dash.nichd.nih.gov/>

Table 1: Estimated risk of respiratory morbidity among neonates not exposed and exposed to antenatal steroids, stratified by week of gestation and planned mode of delivery

Week of Gestation at Presentation	Planned Vaginal Delivery		Planned Cesarean Delivery	
	No ALPS % (95% CI)	ALPS % (95% CI)	No ALPS % (95% CI)	ALPS % (95% CI)
34 weeks	21.1 (17.6-24.6)	17.4 (14.2-20.6)	36.7 (29.8-43.7)	31.4 (24.5-37.9)
35 weeks	11.8 (9.5-14.1)	9.5 (7.6-11.5)	22.5 (17.6-27.4)	18.6 (14.3-22.9)
36 weeks	6.8 (5.1-8.5)	5.4 (4.0-6.9)	13.7 (9.8-17.5)	11.1 (7.8-14.3)

Table 2: Estimated risk of severe respiratory complications among neonates not exposed and exposed to antenatal steroids, stratified by week of gestation and planned mode of delivery

Week of Gestation at Presentation	Planned Vaginal Delivery		Planned Cesarean Delivery	
	No ALPS % (95% CI)	ALPS % (95% CI)	No ALPS % (95% CI)	ALPS % (95% CI)
34 weeks	16.2 (13.4-18.9)	10.7 (8.5-13.0)	32.2 (25.7-38.7)	22.9 (17.5-28.4)
35 weeks	8.8 (7.2-10.3)	4.7 (3.5-6.9)	19.1 (14.9-23.3)	12.9 (9.7-16.1)
36 weeks	4.6 (3.3-5.9)	2.9 (2.0-3.8)	10.5 (7.3-13.7)	6.9 (4.6-9.1)

Supplemental Table 1: Sample sizes of strata

Week of Gestation at Presentation	Planned VD n=2,351	Planned CD n=474
34 weeks	644	98
35 weeks	887	213
36 weeks	820	163

Supplemental Table 2: Distribution of patent factors between the control and treatment groups

Factor	Control n=1,399	Treatment n=1,426	P value
Gestational age at randomization (days) ¹	248.4 (5.5)	248.6 (5.4)	0.31
Gestational age at randomization (weeks)			0.21
34 weeks	388 (27.7%)	354 (24.8%)	
35 weeks	534 (38.2%)	566 (26.7%)	
36 weeks	477 (34.1%)	506 (35.5%)	
Planned Mode of Delivery			0.70
Vaginal	1,173 (83.8%)	1,178 (82.6%)	
Cesarean	226 (16.2%)	248 (17.4%)	

¹ Presented as mean (standard deviation).

Supplemental Table 3: Observed rates and corresponding 95% confidence intervals of respiratory morbidity among the neonates not exposed and exposed to antenatal steroids, stratified by planned mode of delivery and week of gestation

Week of Gestation at Presentation	Planned Vaginal Delivery		Planned Cesarean Delivery	
	No ALPS % (95% CI)	ALPS % (95% CI)	No ALPS % (95% CI)	ALPS % (95% CI)
34 weeks	20.5 (16.2-24.8)	17.6 (13.3-21.9)	39.2 (25.6-52.7)	31.9 (18.4-45.4)
35 weeks	12.1 (9.1-15.2)	10.2 (7.4-13.0)	25.8 (17.0-34.5)	12.7 (6.1-18.0)
36 weeks	5.3 (3.1-7.5)	6.2 (3.9-8.5)	16.7 (8.3-25.0)	11.8 (4.9-18.7)

Supplemental Table 4: Unadjusted and adjusted odds of respiratory morbidity

Model Term	Unadjusted Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)
Treatment Group		
Placebo	Reference	Reference
Antenatal Steroids	0.80 (0.63, 0.97)	0.78 (0.62, 0.98)
Planned Mode of Delivery		
Vaginal	Reference	Reference
Cesarean	1.99 (1.54, 2.57)	2.19 (1.68, 2.85)
Week of Gestation (days)	0.91 (0.89, 0.93)	0.91 (0.89, 0.93)


Supplemental Table 5: Observed rates and corresponding 95% confidence intervals of severe respiratory complications among the neonates not exposed to antenatal steroids, stratified by planned mode of delivery and week of gestation

Week of Gestation at Presentation	Planned Vaginal Delivery		Planned Cesarean Delivery	
	No ALPS	ALPS	No ALPS	ALPS
34 weeks	15.7 (11.8-19.6)	13.7 (9.8-17.5)	37.3 (23.9-50.7)	23.4 (11.1-35.6)
35 weeks	10.5 (7.6-13.4)	6.2 (4.0-8.5)	23.7 (15.2-32.2)	9.5 (4.1-14.8)
36 weeks	4.3 (2.3-6.2)	3.3 (1.6-5.0)	12.8 (5.4-20.3)	8.2 (2.4-14.1)


Supplemental Table 6: Unadjusted and adjusted odds of severe respiratory complications

Model Term	Unadjusted Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)
Treatment Group		
Placebo	Reference	Reference
Antenatal Steroids	0.63 (0.49, 0.81)	0.63 (0.48, 0.81)
Planned Mode of Delivery		
Vaginal	Reference	Reference
Cesarean	2.22 (1.68, 2.93)	2.46 (1.85, 3.29)
Week of Gestation (days)	0.91 (0.88, 0.93)	0.91 (0.88, 0.93)


Supplemental Figure 1: Cross-validated receiver operating characteristic curves for model predicting the primary outcome (respiratory morbidity)



Supplemental Figure 2: Calibration plot for the model predicting the primary outcome (respiratory morbidity)



Supplemental Figure 3: Cross-validated receiver operating characteristic curves for the model predicting the secondary outcome (severe respiratory complications)



Supplemental Figure 4: Calibration plot for the model predicting the secondary outcome (severe respiratory complications)

